Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products. It offers endocrinology products for the treatment of diabetes, osteoporosis in postmenopausal women and men, and human growth hormone deficiency and pediatric growth conditions. The Company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, schizophrenia, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and more.

Employee Rating

3.8More
TypePublic
HQIndianapolis, US
Founded1876
Size (employees)38,160 (est)-6%
Websitelilly.com
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Eli Lilly

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer
Melissa Stapleton Barnes

Melissa Stapleton Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno

Enrique A. Conterno

Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry

Stephen F. Fry

Senior Vice President, Human Resources and Diversity
Michael J. Harrington

Michael J. Harrington

Senior Vice President and General Counsel
Johna L. Norton

Johna L. Norton

Senior Vice President, Global Quality
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Melrose Park, Toronto, Wien and in 141 other locations
Indianapolis, (HQ)
Lilly Corporate Center
Melrose Park,
112 Wharf Rd
Wien,
8-10 Kölblgasse
Toronto,
3650 Danforth Ave
Chuo Ward,
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham,
Erl Wood Manor Sunninghill Road
Show all (196)
Report incorrect company information

Eli Lilly Financials and Metrics

Eli Lilly Revenue

Embed Graph
View revenue for all periods
Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.
USD

Market capitalization (12-Dec-2018)

121.1b

Closing stock price (12-Dec-2018)

114.3

Cash (30-Sep-2018)

9.0b
Eli Lilly's current market capitalization is $121.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1b19.6b20.0b21.2b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9b4.9b5.0b5.7b

Gross profit

18.2b14.7b14.9b15.6b
Quarterly
USDQ3, 2016Q2, 2017Q3, 2017Q1, 2018

Revenue

5.7b5.7b

Pre tax profit

1.4b

Income tax expense

36.0m

Net Income

778.0m1.0b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

3.8b3.9b3.7b4.6b

Accounts Receivable

588.4m566.7m558.6m736.9m

Inventories

2.9b2.7b3.4b3.6b

Current Assets

13.1b12.2b12.6b15.1b
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q3, 2018

Cash

3.9b3.2b3.5b9.0b

Inventories

3.0b4.3b4.1b

Current Assets

12.3b12.6b

Goodwill

4.2b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7b2.4b2.4b2.7b

Cash From Operating Activities

5.7b4.4b2.8b4.9b

Purchases of PP&E

(1.0b)(1.2b)(1.1b)(1.0b)

Cash From Investing Activities

(2.1b)(3.9b)26.8m(3.1b)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q2, 2016Q3, 2016Q2, 2017Q2, 2018Q3, 2018

Net Income

727.9m1.5b2.0b1.9b2.1b

Depreciation and Amortization

348.8m697.2m726.0m1.2b848.0m

Cash From Operating Activities

272.3m1.3b2.0b2.0b

Cash From Investing Activities

388.4m(80.5m)(2.0b)2.6b
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AurKa PharmaMay 15, 2018$575 m
ARMO BioSciences IncMay 11, 2018$1.60 b
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.40 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.50 b
Report incorrect company information

Eli Lilly Online and Social Media Presence

Embed Graph
Report incorrect company information

Eli Lilly News and Updates

Diabetic Therapeutic Drugs Global Market 2018: Key Players – Pfizer, Novartis, AstraZeneca, Eli Lilly, Merck

Wiseguyreports.Com adds “Diabetic Therapeutic Drugs Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Diabetes Management Global Market 2018-2023: Abbott, Bayer, Eli Lilly, Sanofi, Dexcom, Medtronic

Wiseguyreports.Com Publish New Market Research Report On -“Diabetes Management Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2023” Posted via Industry Today. Follow us on Twitter @IndustryToday

Breast cancer therapeutic Market Size, Market Share And Industry Growth Analysis, market trends, Forecast 2025 by AstraZeneca, Eisai,Eli Lilly ,Company,F. Hoffmann-La Roche

Global Breast cancer therapeutic Market is expected to grow at a Compound Annual Growth Rate (CAGR) of +11.63%. The base year considered for the study is 2018 and the forecast period considered is 2018 To 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Injection Pen Market Outlook with Expected 9.5% CAGR 2018-2025 | Global key Players Owen Mumford Ltd, Eli Lilly And Company, GlaxoSmithKline plc, Mylan N.V., Astra Zeneca, Novo Nordisk

Qurate Business Intelligence Adds “Injection Pen Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Diabetes Drug Market Report 2018-2024 Featuring Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson & Boehringer Ingelheim

DUBLIN, Nov. 26, 2018 /PRNewswire/ -- The "Diabetes Drug Market, Oral, Injection, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering. Global diabetes drug market is expected to surpass US$ 76 Billion by the end of the year 2024 Rising global diabetes...

Human Recombinant Insulin Market Increased International Trends and Opening New Opportunities till 2026 By Global Key Players Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A.

#Summary: Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter…
Show more
Report incorrect company information

Eli Lilly Company Life and Culture

Report incorrect company information

Eli Lilly Frequently Asked Questions

  • When was Eli Lilly founded?

    Eli Lilly was founded in 1876.

  • Who are Eli Lilly key executives?

    Eli Lilly's key executives are David A. Ricks, Melissa Stapleton Barnes and Enrique A. Conterno.

  • How many employees does Eli Lilly have?

    Eli Lilly has 38,160 employees.

  • What is Eli Lilly revenue?

    Latest Eli Lilly annual revenue is $21.2 b.

  • What is Eli Lilly revenue per employee?

    Latest Eli Lilly revenue per employee is $556.1 k.

  • Who are Eli Lilly competitors?

    Competitors of Eli Lilly include Pfizer, GlaxoSmithKline and Merck.

  • Where is Eli Lilly headquarters?

    Eli Lilly headquarters is located at Lilly Corporate Center , Indianapolis.

  • Where are Eli Lilly offices?

    Eli Lilly has offices in Indianapolis, Melrose Park, Toronto, Wien and in 141 other locations.

  • How many offices does Eli Lilly have?

    Eli Lilly has 196 offices.